evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

5 questions · 5 findings · 1 reviews · Airways

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 20%High 4 · 80%

Mepolizumab intravenous (IV) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Mepolizumab intravenous (IV) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review

Reslizumab intravenous (IV) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Reslizumab intravenous (IV) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review

Reslizumab subcutaneous (SC) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Reslizumab subcutaneous (SC) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab subcutaneous (SC) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Benralizumab subcutaneous (SC) leads to higher clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review

Mepolizumab subcutaneous (SC) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Mepolizumab subcutaneous (SC) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review